Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • May 29

    Regeneron Completes Secondary Offering of Common Stock Held by Sanofi
  • May 29

    Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time


  • 2020 Annual Meeting of Shareholders
    Jun 12
    10:30 AM EDT
    Jun 12, 2020 | 10:30 AM EDT

  • Regeneron Oncology Investor Event, ASCO 2020
    Jun 1
    4:30 PM EDT
    Jun 1, 2020 | 4:30 PM EDT